MX2016003016A - Pruebas diagnosticas moleculares para cancer pulmonar. - Google Patents
Pruebas diagnosticas moleculares para cancer pulmonar.Info
- Publication number
- MX2016003016A MX2016003016A MX2016003016A MX2016003016A MX2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- test
- diagnostic test
- molecular diagnostic
- responsiveness
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 230000004043 responsiveness Effects 0.000 abstract 2
- 238000011285 therapeutic regimen Methods 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000005971 DNA damage repair Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos y composiciones para la identificación de una prueba diagnóstica molecular para cáncer de pulmón. La prueba define un subtipo molecular deficiente para la reparación del daño del DNA, novedoso y hace posible la clasificación de un paciente dentro de este subtipo. La presente invención puede utilizarse para determinar si los pacientes con NSCLC son sensibles o no sensibles desde el punto de vista clínico a un régimen terapéutico antes de la administración de cualquier quimioterapia. Esta prueba puede utilizarse con diferentes fármacos que afecten directa o indirectamente el daño o la reparación del DNA, como puede ser los múltiples fármacos quimioterapéuticos, citotóxicos, normales que actualmente se utilizan. En particular, la presente invención se dirige al uso de ciertas combinaciones de marcadores predictivos, en donde la expresión de los marcadores predictivos se correlaciona con la sensibilidad o no sensibilidad a un régimen terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316024.7A GB201316024D0 (en) | 2013-09-09 | 2013-09-09 | Molecular diagnostic test for lung cancer |
| PCT/GB2014/052728 WO2015033173A1 (en) | 2013-09-09 | 2014-09-09 | Molecular diagnostic test for lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003016A true MX2016003016A (es) | 2016-06-24 |
Family
ID=49486938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003016A MX2016003016A (es) | 2013-09-09 | 2014-09-09 | Pruebas diagnosticas moleculares para cancer pulmonar. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160222459A1 (es) |
| EP (1) | EP3044328A1 (es) |
| JP (1) | JP2016536001A (es) |
| KR (1) | KR20160052729A (es) |
| CN (1) | CN105874079A (es) |
| AU (1) | AU2014316824A1 (es) |
| CA (1) | CA2923528A1 (es) |
| GB (1) | GB201316024D0 (es) |
| IL (1) | IL244472A0 (es) |
| MX (1) | MX2016003016A (es) |
| SG (1) | SG11201601722XA (es) |
| WO (1) | WO2015033173A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| US20140136508A1 (en) | 2012-11-09 | 2014-05-15 | Palo Alto Research Center Incorporated | Computer-Implemented System And Method For Providing Website Navigation Recommendations |
| KR20250091304A (ko) | 2013-03-15 | 2025-06-20 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| ES2753360T3 (es) | 2014-05-29 | 2020-04-08 | Spring Bioscience Corp | Anticuerpos contra PD-L1 y usos de los mismos |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| US10438130B2 (en) * | 2015-12-01 | 2019-10-08 | Palo Alto Research Center Incorporated | Computer-implemented system and method for relational time series learning |
| US11436656B2 (en) | 2016-03-18 | 2022-09-06 | Palo Alto Research Center Incorporated | System and method for a real-time egocentric collaborative filter on large datasets |
| CN109844539A (zh) * | 2016-03-21 | 2019-06-04 | 南托米克斯有限责任公司 | 用于非小细胞肺癌患者分层的ercc1和其他标志物 |
| US11093834B2 (en) | 2016-07-06 | 2021-08-17 | Palo Alto Research Center Incorporated | Computer-implemented system and method for predicting activity outcome based on user attention |
| CN106755322A (zh) * | 2016-11-25 | 2017-05-31 | 苏州首度基因科技有限责任公司 | 一种预测肺癌转移的试剂盒及其使用方法 |
| KR101875462B1 (ko) * | 2016-12-29 | 2018-07-06 | 강원대학교산학협력단 | FosB 유전자 프로모터를 이용한 종양 환자의 항암제 내성 진단용 바이오마커 및 이를 이용한 항암제 내성 진단용 킷트 |
| AU2018243667A1 (en) | 2017-03-31 | 2019-10-17 | Seagen Inc. | Combinations of Chk1- and Wee1 - inhibitors |
| CN107142298A (zh) * | 2017-06-15 | 2017-09-08 | 大连理工大学 | 一种细胞周期阻滞剂6bar在人肺癌细胞中的应用 |
| KR102905526B1 (ko) | 2017-06-27 | 2025-12-30 | 주식회사 뉴라클사이언스 | 항-fam19a5 항체 및 이의 용도 |
| WO2019069229A1 (en) * | 2017-10-02 | 2019-04-11 | Neuracle Science Co., Ltd. | USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS |
| US11839614B2 (en) * | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
| US11681953B2 (en) * | 2018-04-13 | 2023-06-20 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay development and testing |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| CN109880903B (zh) * | 2019-03-01 | 2021-12-14 | 南京医科大学 | 一种用于非小细胞肺癌辅助诊断的snp标志物及其应用 |
| US20220249484A1 (en) * | 2019-05-17 | 2022-08-11 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies |
| CN110246544B (zh) * | 2019-05-17 | 2021-03-19 | 暨南大学 | 一种基于整合分析的生物标志物选择方法及系统 |
| CN110456085A (zh) * | 2019-09-20 | 2019-11-15 | 四川大学华西医院 | Syt12自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN111381047A (zh) * | 2020-03-19 | 2020-07-07 | 四川大学华西第二医院 | Fbxo2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| JP7464977B2 (ja) * | 2020-06-10 | 2024-04-10 | 国立大学法人東京農工大学 | イヌ中皮腫細胞株 |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| CN112522409A (zh) * | 2020-12-29 | 2021-03-19 | 北京泱深生物信息技术有限公司 | 基因标志物组合在肺癌筛查和预后判断中的应用 |
| CN114540504B (zh) * | 2022-04-27 | 2022-07-08 | 广州万德基因医学科技有限公司 | 用于预测肺鳞癌患者免疫疗效的标志物组及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| JP2006211994A (ja) * | 2005-02-07 | 2006-08-17 | Seibutsu Yuki Kagaku Kenkyusho:Kk | 非小細胞肺癌に対する抗癌剤の抗癌特性決定方法 |
| CA2624086A1 (en) * | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP3301446B1 (en) * | 2009-02-11 | 2020-04-15 | Caris MPI, Inc. | Molecular profiling of tumors |
| KR20130056855A (ko) * | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
| MY166040A (en) * | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
-
2013
- 2013-09-09 GB GBGB1316024.7A patent/GB201316024D0/en not_active Ceased
-
2014
- 2014-09-09 EP EP14766776.0A patent/EP3044328A1/en not_active Withdrawn
- 2014-09-09 JP JP2016539639A patent/JP2016536001A/ja active Pending
- 2014-09-09 MX MX2016003016A patent/MX2016003016A/es unknown
- 2014-09-09 WO PCT/GB2014/052728 patent/WO2015033173A1/en not_active Ceased
- 2014-09-09 CN CN201480058968.8A patent/CN105874079A/zh active Pending
- 2014-09-09 SG SG11201601722XA patent/SG11201601722XA/en unknown
- 2014-09-09 CA CA2923528A patent/CA2923528A1/en not_active Abandoned
- 2014-09-09 KR KR1020167009430A patent/KR20160052729A/ko not_active Withdrawn
- 2014-09-09 US US14/917,913 patent/US20160222459A1/en not_active Abandoned
- 2014-09-09 AU AU2014316824A patent/AU2014316824A1/en not_active Abandoned
-
2016
- 2016-03-07 IL IL244472A patent/IL244472A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016536001A (ja) | 2016-11-24 |
| IL244472A0 (en) | 2016-04-21 |
| EP3044328A1 (en) | 2016-07-20 |
| KR20160052729A (ko) | 2016-05-12 |
| CA2923528A1 (en) | 2015-03-12 |
| US20160222459A1 (en) | 2016-08-04 |
| AU2014316824A1 (en) | 2016-04-21 |
| WO2015033173A1 (en) | 2015-03-12 |
| CN105874079A (zh) | 2016-08-17 |
| GB201316024D0 (en) | 2013-10-23 |
| SG11201601722XA (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003016A (es) | Pruebas diagnosticas moleculares para cancer pulmonar. | |
| MY166040A (en) | Molecular diagnostic test for cancer | |
| MX2016003077A (es) | Prueba diagnostica molecular para cancer esofagico. | |
| SG195208A1 (en) | Molecular diagnostic test for cancer | |
| MX2015006955A (es) | Prueba de diagnostico molecular para cancer. | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
| WO2013096845A3 (en) | Methods for diagnosis of lung cancer | |
| WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| MY180365A (en) | Markers of tumor cell response to anti-cancer therapy | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
| MX381399B (es) | Formulaciones de coenzima q10 y métodos de uso. | |
| AR100353A1 (es) | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 | |
| SI2900279T1 (sl) | GRPR-antagonisti za detekcijo, diagnozo in zdravljenje GRPR-pozitivnega raka | |
| MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
| IL244902A0 (en) | Derivatives of aminochroman, aminothiochroman and amino-1,2,3,4-tetrahydroquinoline, pharmaceutical compositions containing them and their use in treatment | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| BR112015020054A2 (pt) | Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa |